25 January 2022, Published on Integrative Cancer Therapies (IF 3.538) © SAGE Publications Inc
Liver cancer! A very “desperate” illness. Although liver cancer can be cured by radical hepatectomy to some extent with the progress of medicine, it is still the third most lethal cancer in the world. Poor postoperative recovery accounts for 70-85% of patients with primary liver cancer! This is a daunting ratio. In order to avoid this disease as much as possible, humans have discovered many foods with anti-cancer effects, and mushrooms are one of them.
Shiitake has been recognized as a functional anti-cancer food all over the world, and many studies have been carried out. Scientists recently conducted clinic trial on the role of active hexose, an active ingredient in shiitake, in preventing adverse symptoms after liver cancer surgery. Researchers at Hokkaido University Graduate School of Medicine tested whether active hexose has a preventive effect and effectiveness on recurrence after liver-cancer resection. The study was published on Integrative Cancer Therapies on January 25, 2022.
In this study, 29 patients undergoing hepatectomy for liver cancer were treated with active hexose after surgery. The mean age of the subjects was 68 years (36 – 84 years), and the male-to-female ratio was 27:2. The treatment period is about two years. Studies have shown that 48% of all patients who continue to receive treatment do not recur after liver cancer resection. The detection indexes such as serum albumin index recovered to the preoperative level at 6 months after operation, and the proportion of lymphocytes did not change, and the inflammatory markers (NLR, PNI, SII) were at normal levels. In addition, toxicity or related adverse events were noted in all patients receiving the active hexose.
Kamiyama, T., Orimo, T., Wakayama, K., Kakisaka, T., Shimada, S., Nagatsu, A., … & Taketomi, A. (2022). Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia. Integrative Cancer Therapies, 21, 15347354211073066.
